还没有账号立即注册
登录即代表您已同意《广州尊龙凯时信息科技股份有限公司隐私政策》
登录即代表您已同意《广州尊龙凯时信息科技股份有限公司隐私政策》
已有账号登录账号
Case Introduction of Jianfan Biological ERP Project
Zhuhai Jianfan Biotechnology Co., Ltd
Established in 1989, specializing in the research and development, production, and sales of biomaterials and high-tech medical devices, it is the first A-share ChiNext listed company in China to focus on blood purification products (stock code: 300529). At present, the company's market value is firmly among the top listed medical device companies in China, with companies paying taxes of over 100 million yuan in consecutive years, and has been selected as one of the top 100 potential listed companies in Forbes China in 2017.
Jianfan has won the "2009 National Science and Technology Progress Second Prize", and has been listed as one of the "Forbes China Top 100 Potential Enterprises" from 2010 to 2011. In 2011, it was recognized as a "Key High tech Enterprise of the National Torch Program", and was one of the first enterprises in China and the second enterprise in Guangdong Province to pass the GMP inspection for medical devices. It was selected for the 2012 National Industrial Revitalization and Technological Transformation Project, the 2012 National Major Science and Technology Achievement Transformation Project, and the 2012 National Key Science and Technology Achievement Transformation Project The 2012 Guangdong Province Strategic Emerging Industry Core Technology Research Project and the 2014 National 12th Five Year Plan for Science and Technology Support Project. The company's products have passed CE certification and ISO international quality management system certification, and have undertaken two "National Key New Product Projects" and three "National Torch Program Projects". They have been approved to establish the Guangdong Blood Purification Engineering Technology Research and Development Center, Provincial Enterprise Technology Center, Postdoctoral Research Workstation, and Academician Workstation. The company has strong research and development, production capabilities, and a sales network throughout the country. The product technology has reached the international advanced level, and the main products "DNA immune adsorption column", "plasma bilirubin adsorber", and "resin blood perfusion device" have a high market share. The world-class blood purification research and production base (Jianfan Science and Technology Park) independently invested and built by the company has been successfully completed and put into operation in 2015.